×
S&P 500   3,814.27 (-0.19%)
DOW   30,991.60 (+0.14%)
QQQ   283.85 (+0.11%)
AAPL   139.79 (+1.71%)
MSFT   260.53 (+1.58%)
META   164.22 (+2.20%)
GOOGL   2,232.09 (-0.36%)
AMZN   109.39 (+1.85%)
TSLA   685.35 (-1.81%)
NVDA   155.00 (-3.02%)
NIO   21.78 (-2.59%)
BABA   115.64 (-0.96%)
AMD   77.92 (-3.54%)
MU   55.90 (-3.39%)
CGC   3.52 (-2.49%)
T   21.00 (+1.89%)
GE   63.49 (-3.63%)
F   11.56 (-2.12%)
DIS   95.98 (+0.06%)
AMC   13.86 (+3.59%)
PFE   51.19 (+1.05%)
PYPL   71.44 (-0.53%)
NFLX   177.92 (-0.94%)
S&P 500   3,814.27 (-0.19%)
DOW   30,991.60 (+0.14%)
QQQ   283.85 (+0.11%)
AAPL   139.79 (+1.71%)
MSFT   260.53 (+1.58%)
META   164.22 (+2.20%)
GOOGL   2,232.09 (-0.36%)
AMZN   109.39 (+1.85%)
TSLA   685.35 (-1.81%)
NVDA   155.00 (-3.02%)
NIO   21.78 (-2.59%)
BABA   115.64 (-0.96%)
AMD   77.92 (-3.54%)
MU   55.90 (-3.39%)
CGC   3.52 (-2.49%)
T   21.00 (+1.89%)
GE   63.49 (-3.63%)
F   11.56 (-2.12%)
DIS   95.98 (+0.06%)
AMC   13.86 (+3.59%)
PFE   51.19 (+1.05%)
PYPL   71.44 (-0.53%)
NFLX   177.92 (-0.94%)
S&P 500   3,814.27 (-0.19%)
DOW   30,991.60 (+0.14%)
QQQ   283.85 (+0.11%)
AAPL   139.79 (+1.71%)
MSFT   260.53 (+1.58%)
META   164.22 (+2.20%)
GOOGL   2,232.09 (-0.36%)
AMZN   109.39 (+1.85%)
TSLA   685.35 (-1.81%)
NVDA   155.00 (-3.02%)
NIO   21.78 (-2.59%)
BABA   115.64 (-0.96%)
AMD   77.92 (-3.54%)
MU   55.90 (-3.39%)
CGC   3.52 (-2.49%)
T   21.00 (+1.89%)
GE   63.49 (-3.63%)
F   11.56 (-2.12%)
DIS   95.98 (+0.06%)
AMC   13.86 (+3.59%)
PFE   51.19 (+1.05%)
PYPL   71.44 (-0.53%)
NFLX   177.92 (-0.94%)
S&P 500   3,814.27 (-0.19%)
DOW   30,991.60 (+0.14%)
QQQ   283.85 (+0.11%)
AAPL   139.79 (+1.71%)
MSFT   260.53 (+1.58%)
META   164.22 (+2.20%)
GOOGL   2,232.09 (-0.36%)
AMZN   109.39 (+1.85%)
TSLA   685.35 (-1.81%)
NVDA   155.00 (-3.02%)
NIO   21.78 (-2.59%)
BABA   115.64 (-0.96%)
AMD   77.92 (-3.54%)
MU   55.90 (-3.39%)
CGC   3.52 (-2.49%)
T   21.00 (+1.89%)
GE   63.49 (-3.63%)
F   11.56 (-2.12%)
DIS   95.98 (+0.06%)
AMC   13.86 (+3.59%)
PFE   51.19 (+1.05%)
PYPL   71.44 (-0.53%)
NFLX   177.92 (-0.94%)
NASDAQ:FLGT

Fulgent Genetics Stock Forecast, Price & News

$54.58
-0.26 (-0.47%)
(As of 06/29/2022 03:34 PM ET)
Add
Compare
Today's Range
$53.96
$55.56
50-Day Range
$47.98
$59.66
52-Week Range
$47.34
$112.00
Volume
7,107 shs
Average Volume
433,489 shs
Market Capitalization
$1.66 billion
P/E Ratio
3.69
Dividend Yield
N/A
Price Target
$86.67
30 days | 90 days | 365 days | Advanced Chart

Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Stock Forecast (MarketRank)

Overall MarketRank

2.20 out of 5 stars

Medical Sector

381st out of 1,433 stocks

Medical Laboratories Industry

9th out of 32 stocks

Analyst Opinion: 3.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
Fulgent Genetics logo

About Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

FLGT Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FLGT
Employees
645
Year Founded
N/A

Company Calendar

Last Earnings
5/03/2022
Today
6/29/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$86.67
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$65.00
Forecasted Upside/Downside
+58.8%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
2 Analysts

Profitability

Net Income
$507.36 million
Pretax Margin
64.20%

Debt

Sales & Book Value

Annual Sales
$992.58 million
Cash Flow
$16.95 per share
Book Value
$39.08 per share

Miscellaneous

Free Float
21,381,000
Market Cap
$1.66 billion
Optionable
Not Optionable
Beta
1.57














Fulgent Genetics Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Fulgent Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View analyst ratings for Fulgent Genetics
or view top-rated stocks.

What is Fulgent Genetics' stock price forecast for 2022?

2 equities research analysts have issued twelve-month target prices for Fulgent Genetics' shares. Their FLGT stock forecasts range from $65.00 to $125.00. On average, they predict Fulgent Genetics' stock price to reach $86.67 in the next twelve months. This suggests a possible upside of 58.8% from the stock's current price.
View analysts' price targets for Fulgent Genetics
or view top-rated stocks among Wall Street analysts.

How has Fulgent Genetics' stock performed in 2022?

Fulgent Genetics' stock was trading at $100.59 at the start of the year. Since then, FLGT stock has decreased by 45.7% and is now trading at $54.58.
View the best growth stocks for 2022 here
.

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Fulgent Genetics
.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its quarterly earnings results on Tuesday, May, 3rd. The company reported $4.93 earnings per share for the quarter, topping the consensus estimate of $4.32 by $0.61. The business had revenue of $320.30 million for the quarter, compared to the consensus estimate of $300.50 million. Fulgent Genetics had a net margin of 48.32% and a trailing twelve-month return on equity of 41.13%. The firm's revenue for the quarter was down 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.51 earnings per share.
View Fulgent Genetics' earnings history
.

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $125.00 million-$125.00 million, compared to the consensus revenue estimate of $134.35 million.

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the following people:
  • Mr. Ming Hsieh, Chairman & CEO (Age 66, Pay $5.66M)
  • Mr. Jian Xie, COO & Pres (Age 56, Pay $704.62k)
  • Mr. Paul Kim, Chief Financial Officer (Age 55, Pay $669.98k)
  • Dr. Han Lin Gao D.A.B.M.G., F.A.C.M.G., FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director (Age 55, Pay $630.54k)
  • Ms. Natalie Prescott, VP of Legal & Deputy Gen. Counsel
  • Ms. Doreen Ng, VP of Operations & Compliance and GM of Houston Office
  • Mr. Jakub Sram, VP of Bus. Devel. & Sales
  • Ms. Ellen Tsui, VP of HR
  • Mr. Brandon Perthuis, Chief Commercial Officer
  • Dr. Lawrence M. Weiss M.D., Chief Medical Officer (Age 65)

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Square (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.86%), Vanguard Group Inc. (4.42%), State Street Corp (2.30%), Aaron Wealth Advisors LLC (1.07%), Pacer Advisors Inc. (0.99%) and Invesco Ltd. (0.98%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends for Fulgent Genetics
.

Which institutional investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including Skandinaviska Enskilda Banken AB publ , BlackRock Inc., PEAK6 Investments LLC, Jupiter Asset Management Ltd., Northern Trust Corp, Gerber Kawasaki Wealth & Investment Management, Capital Fund Management S.A., and Group One Trading L.P.. Company insiders that have sold Fulgent Genetics company stock in the last two years include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics
or view top insider-selling stocks.

Which institutional investors are buying Fulgent Genetics stock?

FLGT stock was purchased by a variety of institutional investors in the last quarter, including Aaron Wealth Advisors LLC, Pacer Advisors Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., State Street Corp, JPMorgan Chase & Co., Royce & Associates LP, and WINTON GROUP Ltd.
View insider buying and selling activity for Fulgent Genetics
or or view top insider-buying stocks.

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $54.58.

How much money does Fulgent Genetics make?

Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $1.66 billion and generates $992.58 million in revenue each year. The company earns $507.36 million in net income (profit) each year or $14.789990 on an earnings per share basis.

How many employees does Fulgent Genetics have?

Fulgent Genetics employs 645 workers across the globe.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for Fulgent Genetics is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at [email protected], or via fax at 626-454-1667.

This page (NASDAQ:FLGT) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.